Tumor Infiltrating Lymphocytes (TIL): clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Tumor Infiltrating Lymphocytes (TIL)

• A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
  NCT05142475 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
  NCT06530303 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
• Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
  NCT05681780 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
  NCT06532812 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
  NCT06538012 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
  NCT06532799 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Tumor Infiltrating Lymphocytes (TIL)?

6 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.